This assay is capable of measuring the metastatic potential and/or chemoresistance of single living cancer cells.
[Detail]
- This technology addresses problems associated with existing bispecific antibodydrugs, such as short serum half-life, drug heterogeneity and complicated drug manufacturing processes- This technology can be used as a platform technology to expand a variety of cancer indications
[Detail]
|< <- | [3018] [3019] [3020] [3021] [3022] [3023] [3024] [3025] [3026] [3027] [3028] | -> >| |